Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPVX01
- Development stage
- Preclinical
- Lead developer
- Stablepharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SPVX01 is a preclinical-stage, fridge-free combination vaccine candidate being developed by Stablepharma for the prevention of tetanus and diphtheria (Td). It is formulated using Stablepharma's proprietary StablevaX technology, which reformulates temperature-sensitive vaccines into thermostable products that do not require cold-chain storage. SPVX01 is designed for delivery via a pre-filled syringe delivery system, where the dry, stabilized vaccine is reconstituted immediately prior to administration.
- Other names
- SPVX-01SPVX01SPVX 01
02
Targets
Diphtheria toxin
Beyond the preview
Go deeper on SPVX01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPVX01.